Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGISTA-K
jRCTs031220568Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in hyperkalemia and heart failure with reduced ejection fraction (HFrEF) comparing Lokelma arm with Placebo arm (2 arms). Primary endpoint: Achievement of spironolactone 50 mg/day without rescue therapy during the double-blind period. Started Oct 2023; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCTs031220568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220568.